Homologous Recombination Deficiency (HRD)-positive high-grade serous ovarian carcinoma (B...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | RF-OVARIAN-HRD-POSITIVE-ACTIONABLE |
|---|---|
| Type | Signal d’alerte |
| État | reviewed 2026-04-27 | pending_clinical_signoff |
| Maladies | DIS-OVARIAN |
| Sources | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 SRC-NOVA-MIRZA-2016 SRC-PRIMA-GONZALEZ-MARTIN-2019 |
Origine du drapeau rouge
| Définition | Homologous Recombination Deficiency (HRD)-positive high-grade serous ovarian carcinoma (BRCA1/2 mutation OR Genomic Instability Score ≥42). PARPi maintenance after platinum-based induction is treatment-defining: niraparib (PRIMA — mPFS 21.9 vs 10.4 mo HRD-pos), olaparib + bevacizumab (PAOLA-1 — mPFS 37.2 vs 17.7 mo HRD-pos). |
|---|---|
| Direction clinique | intensifier |
| Catégorie | high-risk-biology |
| Algorithme de décalage | ALGO-OVARIAN-ADVANCED-1L, ALGO-OVARIAN-2L |
Logique de déclenchement
{
"any_of": [
{
"finding": "hrd_status",
"value": "HRD-positive"
},
{
"finding": "hrd_status",
"value": "positive"
},
{
"comparator": ">=",
"finding": "genomic_instability_score",
"threshold": 42
}
],
"type": "biomarker"
}
Notes
HRD assays: Myriad myChoice CDx (companion for olaparib + bev, niraparib), FoundationOne CDx HRD. GIS captures BRCAness (LOH + TAI + LST signatures) in tumors WT for BRCA1/2. HRD-negative HGSC has minimal PARPi maintenance benefit (PRIMA mPFS 8.1 vs 5.4 mo) — bev maintenance preferred. Coexists with RF-OVARIAN-BRCA-MUT-ACTIONABLE (BRCA-mut subset is HRD-positive by definition); RF-OVARIAN-HRD-ACTIONABILITY is the older composite version.
Utilisé par
Algorithmes
ALGO-OVARIAN-2L- ALGO-OVARIAN-2LALGO-OVARIAN-ADVANCED-1L- ALGO-OVARIAN-ADVANCED-1L
Chapitres du manuel
HB-OVARIAN-MAINTENANCE-1L- Advanced ovarian cancer: HRD/BRCA first-line maintenance reasoning
Questions du manuel
HQ-OVARIAN-MAINTENANCE-1L-002- HQ-OVARIAN-MAINTENANCE-1L-002